{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T12:09:18Z","timestamp":1759838958188},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Soc Psychiatry Psychiatr Epidemiol"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1007\/s00127-005-0852-y","type":"journal-article","created":{"date-parts":[[2004,12,29]],"date-time":"2004-12-29T01:03:49Z","timestamp":1104282229000},"page":"72-77","source":"Crossref","is-referenced-by-count":19,"title":["Impact of regulatory changes on first- and second-generation antipsychotic drug consumption and expenditure in Italy"],"prefix":"10.1007","volume":"40","author":[{"given":"Margherita","family":"Andretta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arcangelo","family":"Ciuna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Letizia","family":"Corbari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corrado","family":"Barbui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00004714-200302000-00006","volume":"23","author":"Barbui","year":"2003","unstructured":"Barbui C, Broglio E, Costa Laia A, D?Agostino S, Enrico F, Ferraro L, Fiorio E, Miletti F, Pietraru C, Poggio L, Tognoni G (2003) Cross-sectional database analysis of antidepressant prescribing in Italy. J Clin Psychopharmacol 23:31?34","journal-title":"J Clin Psychopharmacol"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00004850-200107000-00007","volume":"16","author":"Barbui","year":"2001","unstructured":"Barbui C, Campomori A, Mezzalira L, Da Cas R, Garattini S (2001) Psychotropic drug use in Italy 1984?1999: the impact of a change in reimbursement status. Int Clin Psychopharmacol 16:227?233","journal-title":"Int Clin Psychopharmacol"},{"key":"CR3","first-page":"170","volume":"348","author":"Bozzini","year":"1996","unstructured":"Bozzini L, Martini N (1996) Drug policy?from chaos towards cost-effectiveness. Lancet 348:170?171","journal-title":"Lancet"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1176\/appi.ajp.158.4.518","volume":"158","author":"Chakos","year":"2001","unstructured":"Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B (2001) Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomised trials. Am J Psychiatry 158:518?526","journal-title":"Am J Psychiatry"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0140-6736(95)92647-X","volume":"346","author":"Garattini","year":"1995","unstructured":"Garattini S (1995) Cultural shift in Italy?s drug policy. Lancet 346:5?6","journal-title":"Lancet"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/oxfordjournals.schbul.a006980","volume":"29","author":"Geddes","year":"2003","unstructured":"Geddes J (2003) Generating evidence to inform policy and practice: the example of the second generation ?atypical? antipsychotics. Schizophr Bull 29:105?114","journal-title":"Schizophr Bull"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/bmj.321.7273.1371","volume":"321","author":"Geddes","year":"2000","unstructured":"Geddes J, Freemantle N, Harrison P, Bebbington P for the National Schizophrenia Guideline Development Group (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321:1371?1376","journal-title":"BMJ"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0920-9964(97)85354-6","volume":"19","author":"Jablensky","year":"1997","unstructured":"Jablensky A (1997) The 100-year epidemiology of schizophrenia. Schizophr Res 19:111?125","journal-title":"Schizophr Res"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/bmj.327.7419.819","volume":"327","author":"Jones","year":"2003","unstructured":"Jones G (2003) Prescribing and taking medicines. Concordance is a fine theory but it is mostly not being practised. BMJ 327:819","journal-title":"BMJ"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/bmj.321.7273.1360","volume":"321","author":"Kapur","year":"2000","unstructured":"Kapur S, Remington G (2000) Atypical antipsychotics. Patients value the lower incidence of extrapyramidal side effects. BMJ 321:1360?1361","journal-title":"BMJ"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1046\/j.1440-1614.2003.01110.x","volume":"37","author":"Mond","year":"2003","unstructured":"Mond J, Morice R, Owen C, Korten A (2003) Use of antipsychotic medications in Australia between July 1995 and December 2001. Aust N Z J Psychiatry 37:55?61","journal-title":"Aust N Z J Psychiatry"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.4088\/JCP.v64n1103","volume":"64","author":"Percudani","year":"2003","unstructured":"Percudani M, Barbui C (2003) Cost and outcome implications of using typical and atypical antipsychotics in ordinary practice in Italy. J Clin Psychiatry 64:1293?1299","journal-title":"J Clin Psychiatry"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0924-9338(02)00705-8","volume":"17","author":"Santamaria","year":"2002","unstructured":"Santamaria B, Perez M, Montero D, Madurga M, de Abajo FJ (2002) Use of antipsychotic agents in Spain through 1985?2000. Eur Psychiatry 17:471?476","journal-title":"Eur Psychiatry"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1176\/ps.48.2.213","volume":"48","author":"Tibaldi","year":"1997","unstructured":"Tibaldi G, Munizza C, Bollini P, Pirfo E, Punzo F, Gramaglia F (1997) Utilization of neuroleptic drugs in Italian mental health services: a survey in Piedmont. Psychiatr Serv 48:213?217","journal-title":"Psychiatr Serv"},{"key":"CR15","unstructured":"WHO (1996) Collaborating Centre for Drug Statistic Methodology. Guidelines for ATC Classification and DDD Assignment. WHO, Oslo"}],"container-title":["Social Psychiatry and Psychiatric Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00127-005-0852-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00127-005-0852-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00127-005-0852-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T08:04:31Z","timestamp":1558598671000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00127-005-0852-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["852"],"URL":"https:\/\/doi.org\/10.1007\/s00127-005-0852-y","relation":{},"ISSN":["0933-7954","1433-9285"],"issn-type":[{"value":"0933-7954","type":"print"},{"value":"1433-9285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}